13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001600004
Total reported value
$1.6B
$1.6B
41 檔
24.6%
According to the latest 13F quarterly dataset, First Light Asset Management, LLC managed an equity portfolio of $1.6B at the end of Q3 2025, spanning 41 distinct U.S. exchange-listed positions.
First Light Asset Management, LLC executed strategic sector rebalancing during Q3 2025, establishing 15 new positions while fully exiting 11 holdings and trimming 13 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | AXGN | Axogen Inc | Stock-Other | 9.76% | -4.16% | +28.18% | |
| 2 | PFMTUSD | Performant Financial CORP | Stock-Other | 8.54% | — | -11.02% | |
| 3 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 8.31% | -5.56% | EXIT | |
| 4 | NEO | Neogenomics Inc | Stock-Healthcare | 7.22% | +4.42% | +45.00% | |
| 5 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 4.30% | -0.67% | — | |
| 6 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 3.70% | -0.45% | +8.95% | |
| 7 | HCAT | Health Catalyst Inc | Stock-Other | 3.61% | +0.08% | +9.86% | |
| 8 | PVLA | Palvella Therapeutics Inc | Stock-Other | 3.20% | -3.79% | — | |
| 9 | TWST | Twist Bioscience CORP | Stock-Other | 3.17% | +0.81% | +26.44% | |
| 10 | LENZ | Lenz Therapeutics Inc | Stock-Other | 3.04% | — | — | |
| 11 | ORGO | Organogenesis Holdings Inc | Stock-Other | 2.98% | -0.74% | EXIT | |
| 12 | ATRC | Atricure Inc | Stock-Other | 2.96% | -0.90% | -12.29% | |
| 13 | ANAB | Anaptysbio Inc | Stock-Other | 2.86% | -0.42% | -72.03% | |
| 14 | SIBN | Si-bone Inc | Stock-Other | 2.66% | +2.00% | +9.53% | |
| 15 | CDTX | Cidara Therapeutics Inc | Stock-Other | 2.64% | — | +62.03% | |
| 16 | IRTC | Irhythm Holdings Inc | Stock-Healthcare | 2.51% | -0.57% | -17.22% | |
| 17 | MDXG | Mimedx Group Inc | Stock-Other | 2.40% | -1.01% | EXIT | |
| 18 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 2.16% | -0.13% | -17.45% | |
| 19 | MASS | 908 Devices Inc | Stock-Other | 2.07% | -0.01% | +135.15% | |
| 20 | ✓ | Merus N V | Stock-Other | 1.99% | — | — | |
| 21 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.72% | -0.10% | — | |
| 22 | GH | Guardant Health Inc | Stock-Healthcare | 1.65% | +1.71% | +117.28% | |
| 23 | KRMD | Koru Medical Systems Inc | Stock-Other | 1.63% | -0.60% | -3.29% | |
| 24 | ✓ | Establishment Labs Holdings In | Stock-Other | 1.62% | -0.28% | +0.29% | |
| 25 | ADMA | Adma Biologics Inc | Stock-Healthcare | 1.48% | — | +12.30% | |
| 26 | IRON | Disc Medicine Inc | Stock-Other | 1.44% | — | — | |
| 27 | VERA | Vera Therapeutics Inc | Stock-Other | 1.39% | -1.13% | EXIT | |
| 28 | NPCE | Neuropace Inc | Stock-Other | 1.32% | -0.14% | -1.47% | |
| 29 | CAI | Caris Life Sciences Inc | Stock-Other | 1.12% | — | -8.83% | |
| 30 | SLP | Simulations Plus Inc | Stock-Other | 1.09% | +0.32% | +114.96% | |
| 31 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.81% | — | -47.86% | |
| 32 | ABVX | Abivax Sa-adr | Stock-Other | 0.77% | — | — | |
| 33 | SENS1GBP | Senseonics Holdings Inc | Stock-Other | 0.74% | — | -49.57% | |
| 34 | RGEN | Repligen CORP | Stock-Healthcare | 0.52% | — | -5.74% | |
| 35 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.52% | — | +61.46% | |
| 36 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.50% | — | — | |
| 37 | EVH | Evolent Health Inc - A | Stock-Other | 0.43% | — | -26.17% | |
| 38 | ALHC | Alignment Healthcare Inc | Stock-Other | 0.33% | — | -47.05% | |
| 39 | RDNT | Radnet Inc | Stock-Healthcare | 0.30% | — | -38.45% | |
| 40 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.30% | -0.12% | — | |
| 41 | BFLY | Butterfly Network Inc | Stock-Other | 0.21% | +0.39% | -79.36% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PFMTUSD | Performant Financial CORP | +4.6% | -11.02% | Add |
| 2 | MASS | 908 Devices Inc | +1.2% | +135.15% | Add |
| 3 | NEO | Neogenomics Inc | +0.7% | +45.00% | Add |
| 4 | CRNX | Crinetics Pharmaceuticals In | +0.4% | +8.95% | Add |
| 5 | SENS1GBP | Senseonics Holdings Inc | +0.4% | -49.57% | Add |
| 6 | KRMD | Koru Medical Systems Inc | +0.3% | -3.29% | Add |
| 7 | GH | Guardant Health Inc | +0.3% | +117.28% | Add |
| 8 | AXGN | Axogen Inc | +0.3% | +28.18% | Add |
| 9 | 260 | Centessa Pharmaceuticals-adr | +0.3% | -15.32% | Trim |
| 10 | GPCR | Structure Therapeutics Inc | +0.3% | +61.46% | Add |
| 11 | SIBN | Si-bone Inc | +0.1% | +9.53% | Add |
| 12 | ✓ | Establishment Labs Holdings In | +0.1% | +0.29% | Add |
| 13 | EVH | Evolent Health Inc - A | -0.2% | -26.17% | Trim |
| 14 | MDXG | Mimedx Group Inc | -0.6% | +89.52% | Add |
| 15 | RGEN | Repligen CORP | -0.8% | -5.74% | Trim |
| 16 | NPCE | Neuropace Inc | -0.9% | -1.47% | Trim |
| 17 | BFLY | Butterfly Network Inc | -1.2% | -79.36% | Trim |
| 18 | IRTC | Irhythm Holdings Inc | -1.4% | -17.22% | Trim |
| 19 | ALHC | Alignment Healthcare Inc | -1.7% | -47.05% | Trim |
| 20 | HCAT | Health Catalyst Inc | -1.8% | +9.86% | Add |
| 21 | RARE | Ultragenyx Pharmaceutical In | -1.8% | -47.86% | Trim |
| 22 | VERA | Vera Therapeutics Inc | -1.8% | -9.93% | Trim |
| 23 | ATRC | Atricure Inc | -1.9% | -12.29% | Trim |
| 24 | TWST | Twist Bioscience CORP | -2.3% | +26.44% | Trim |
| 25 | EWTX | Edgewise Therapeutics Inc | -2.5% | -17.45% | Trim |
| 26 | ANAB | Anaptysbio Inc | -7% | -72.03% | Trim |
| 27 | AMLX | Amylyx Pharmaceuticals Inc | — | NEW | New buy |
| 28 | PVLA | Palvella Therapeutics Inc | — | NEW | New buy |
| 29 | LENZ | Lenz Therapeutics Inc | — | NEW | New buy |
| 30 | ORGO | Organogenesis Holdings Inc | — | NEW | New buy |
| 31 | CDTX | Cidara Therapeutics Inc | — | NEW | New buy |
| 32 | ✓ | Merus N V | — | NEW | New buy |
| 33 | XENE | Xenon Pharmaceuticals Inc | — | EXIT | Sold out |
| 34 | RYTM | Rhythm Pharmaceuticals Inc | — | NEW | New buy |
| 35 | JANX | Janux Therapeutics Inc | — | EXIT | Sold out |
| 36 | ADMA | Adma Biologics Inc | — | NEW | New buy |
| 37 | IRON | Disc Medicine Inc | — | NEW | New buy |
| 38 | CAI | Caris Life Sciences Inc | — | NEW | New buy |
| 39 | SLP | Simulations Plus Inc | — | NEW | New buy |
| 40 | ABVX | Abivax Sa-adr | — | NEW | New buy |
| 41 | ELDN | Eledon Pharmaceuticals Inc | — | EXIT | Sold out |
| 42 | TMDX | Transmedics Group Inc | — | EXIT | Sold out |
| 43 | OSCR | Oscar Health Inc - Class A | — | EXIT | Sold out |
| 44 | FNAUSD | Paragon 28 Inc | — | EXIT | Sold out |
| 45 | MDGL | Madrigal Pharmaceuticals Inc | — | NEW | New buy |
| 46 | INSM | Insmed Inc | — | EXIT | Sold out |
| 47 | TNDM | Tandem Diabetes Care Inc | — | EXIT | Sold out |
| 48 | PODD | Insulet CORP | — | EXIT | Sold out |
| 49 | PCVX | Vaxcyte Inc | — | EXIT | Sold out |
| 50 | RDNT | Radnet Inc | — | NEW | New buy |
According to official SEC Form 13F filings, First Light Asset Management, LLC reported a total U.S. public equity portfolio value of $1.6B across 41 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including AXGN, PFMTUSD, 260) accounted for 24.6% of total reported equity market value during Q3 2025.
Top New Position Initiated
AMLX
市值: $45.6M
Top Position Liquidated / Trimmed
XENE
前期市值: $21.1M
During Q3 2025, First Light Asset Management, LLC's top holdings by market value included AXGN (9.8%)、PFMTUSD (8.5%)、260 (8.3%). The largest single position, AXGN, represented 9.8% of total portfolio value.
In Q3 2025, First Light Asset Management, LLC made 52 total portfolio adjustments, initiating 15 new buys, adding to 13 positions, trimming 13 holdings, and fully liquidating 11 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.